Program
XH-S003 Capsule
Also written as “XH-S003 (A)” and “XH-S003”.
Its studies are mostly in Glomerulonephritis, IGA · Hemoglobinuria, Paroxysmal, led by Fosun Pharma.
Furthest: phase 2, since Feb 27, 20254 company-led studies, 1 open or runningNext primary completion: Sep 30, 2029
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Fosun Pharma | 41 open or running | phase 2since Feb 27, 2025 | Jul 7, 2023 | Sep 30, 2029NCT07657052 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 7, 2023First study: phase 1 study in HealthyFirst studyNCT05946876 · 77 enrolled · Australia
- Feb 15, 2024Phase 1 study in Healthy AdultsNCT06272747 · 36 enrolled · China
- Feb 27, 2025Phase 2 study in Glomerulonephritis, IGANCT07634744 · 25 enrolled · China
- May 29, 2026No phase study in Hemoglobinuria, ParoxysmalNCT07657052 · 26 planned · China
Ahead
- Sep 30, 2029Primary completion: no phase study in Hemoglobinuria, ParoxysmalNCT07657052
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07657052Hemoglobinuria, Paroxysmal · China | – | By invitation | Sep 30, 2029 | 26 |
| NCT07634744Glomerulonephritis, IGA · China | 2 | Completed | Apr 23, 2026 | 25 |
| NCT06272747Healthy Adults · China | 1 | Completed | Jul 30, 2024 | 36 |
| NCT05946876Healthy · Australia | 1 | Completed | Jul 11, 2024 | 77 |
How it is read
Names in the registry
- “XH-S003 Capsule”, 2 entries
- “XH-S003 (A)”, 1 entry
- “XH-S003”, 1 entry
Conditions, from the studies’ own filings
- Glomerulonephritis, IGA, 1 study
- Hemoglobinuria, Paroxysmal, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.